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Abstract—The N, N'-dimethylformamide solvated crystal of the drug nitrofurantoin has been prepared and
analysed by single-crystal X-ray diffraction. The two co-crystallized molecules, in the 1 : 1 stoichiometric
ratio, are linked by a medium/strong N–H···O hydrogen bond (N···O is 2.759 (3) Å) and a weaker C–H···O
interaction to form isolated supramolecular adducts, that in turn are packed into the lattice framework mainly
through C–H···O hydrogen bonds. Two-dimensional fingerprint plots of Hirshfeld surfaces are used to visu-
alize, analyze and compare intermolecular interactions found in the title compound and in similar structures.
DOI: 10.1134/S1063774516040040
INTRODUCTION
Nitrofurantoin (chemical name: (E)-1-[(5-nitro-
2-furyl) methylideneamino]-imidazolidine-2,4-dione)
is an antibacterial drug used for the treatment of lower
urinary tract infections; it works by killing the bacteria
that cause the infection or by preventing the bacteria
from growing. The drug acts in a complex way: inside
the bacterial cells, it is activated by nitrofuran reduc-
tase and the resulting highly reactive nitrofurantoin
reduced form is able to damage the DNA [1]. For the
purpose of development pharmaceutical formula-
tions, it presents the disadvantage of having low solu-
bility, low permeability and hence low bioavailability.
In the last years, the design and synthesis of co-crys-
tals containing active pharmaceutical ingredients have
represented a great opportunity to modify the physico-
chemical properties of solid forms of drugs. Actually,
the pharmaceutical co-crystals display intermolecular
motifs and hence crystal structure different from the
pure drug component, and consequently can exhibit
diverse specific physical properties, such as solubility
and dissolution rate. As a part of our involvement in
the investigation of co-crystals’ structural features [2–4],
we report here the synthesis, structure determination,
and investigation of intercontacts by Hirshfeld surface
analysis [5] of a new solvate co-crystal containing the
active pharmaceutical ingredient nitrofurantoin.
EXPERIMENTAL
Synthesis. Crystals of the title compound have been
prepared dissolving a small amount of nitrofurantoin
in dimethylformamide solvent. After agitation, the
solution have been slowly evaporated at room tem-
perature. Pale yellow crystals were observed after a few
days. All chemicals, purchased from Sigma-Aldrich,
were of analytical or chromatographic grade and were
used without further purification. For C11H13N5O6:
Anal. calcd, (%): C, 42.45; H, 4.21; N, 22.50. Found, (%):
C, 42.48; H, 4.25: N, 22.36.
X-ray structural analysis. X-ray structural analysis.
A single crystal was carefully selected under polarizing
microscope in order to perform its structural analysis
by X-ray diffraction. Crystallographic data were col-
lected on a Nonius Kappa CCD diffractometer at
room temperature using graphite-monochromated
MoKα radiation (λ =  0.71073  Å). Data sets were inte-
grated with the Denzo-SMN package [6] and cor-
rected for Lorentz-polarization effects. The crystal
parameters and other experimental details of the data
collections are summarized in Table 1. The structures
were solved by direct methods (SIR97) [7] and refined
by full-matrix least-squares methods with all non-
hydrogen atoms anisotropic. H atoms of the methyl
groups were included on calculated positions, riding
on their carrier atoms; all other hydrogen atoms were
located in the Difference Fourier map and refined iso-
tropically. All calculations were performed using
SHELXL-97 [8] implemented in the WINGX system
of programs [9]. Selected bond distances and angles1 The article is published in the original.
STRUCTURE
OF ORGANIC COMPOUNDS
612
CRYSTALLOGRAPHY REPORTS  Vol. 61  No. 4  2016
CVETKOVSKI, FERRETTI
are given in Table 2. The drawings were made with
ORTEPIII [10] and Diamond [11].
Crystallographic data have been deposited with the
Cambridge Crystallographic Data Centre, CCDC
number 1447209. Copies of the data can be obtained
free of charge on application to CCDC, 12 union
Road, Cambridge CB2 1EZ, UK (fax: (+44) 1223- 336-
033; e-mail: deposit@ccdc.cam.ac.uk).
Hirshfeld surfaces and fingerprints evaluation.
Molecular Hirshfeld surfaces [5] and their 2D-finger-
print [12, 13] have been evaluated for the present com-
pounds and other related molecules whose structures
have been retrieved from the Cambridge Crystallo-
graphic Database [14] to get additional insight into the
intermolecular interactions of molecular crystals.
Actually, the Hirshfeld surface represents the mole-
cule when interacting with the crystal environment
and the decomposition of this surface gives a ‘molec-
ular fingerprint’, a 2D map indicating not only which
intermolecular interactions are present, but also the rel-
ative area of the surface corresponding to each kind of
interaction. The Hirshfeld surfaces and 2D fingerprint
plots were generated using CrystalExplorer 3.0 [15].
RESULTS AND DISCUSSION
An ORTEPIII view of the asymmetric unit is
shown in Fig. 1. Selected bond distances and angles
are given in Table 2. The crystal is formed by nitrofu-
rantoin and dimethylformamide molecules in 1 : 1
stoichiometric ratio. The drug molecule, excluding
the H atoms, is not far from planar, the maximum dis-
placement from the mean molecular plane being
0.181(2) and 0.298(2) Å for the O4 and O2 atoms,
respectively. The E molecular configuration with
respect to the C4=N3 double bond found in the pure
drug crystal is conserved: the N2–N3–C4–C5 tor-
sion angle is equal to –179.2 (2)°. Bond distances and
angles are regular and are in agreement with those
Table 1. Crystallographic characteristics and X-ray-data-
collection and structure refinement parameters of
C11H13N5O6
System, sp. gr., Z Triclinic, P , 2
a, b, c, Å 6.6391(3), 8.9453(4), 12.9761(7)
α, β, γ, deg 97.160(2), 97.612(3), 106.187(2)
V, Å3 722.92(6)
Dx, g cm−3 1.430
Radiation, λ, Å MoKα, 0.71073
μ, mm–1 0.12
T, K 295
Sample size, mm 0.29 × 0.21 × 0.18
Diffractometer Nonius Kappa CCD
Scan mode φ and ω
Absorption correction,
Tmin, Tmax
None
θmax, deg 28.0
h, k, l ranges –8 ≤ h ≤ 7; –11 ≤ k ≤ 11;
–17 ≤ l ≤ 16
Number of ref lections: 
measured/unique (N1), 
Rint/with I > 3(I) (N2)
5644/3465, 0.025/2224
Refinement method Full-matrix least-squares on F2
Number of refined
parameters
228
R1/wR2 relative to N1 0.097/0.202
R1/wR2 relative to N2 0.063/0.173
S 1.00
∆ρmax/∆ρmin, e/Å3 0.39, −0.23
Program package Denso-SMN [6], SIR97 [7], 
SHELXL [8], WingX [9], 
ORTEPIII [10], Diamond [11]
1
Table 2. Selected bond lengths d (Å) and bond angles ω
(deg)
C1−O1 1.199 (3) C1−N2 1.378 (3)
C1−N1 1.382 (3) C2−O2 1.205 (3)
C2−N1 1.355 (3) C3−N2 1.454 (2)
N2−N3 1.363 (2) C4−N3 1.288 (3)
O4−N4 1.208 (3) O5−N4 1.236 (3)
C9−O6 1.225 (4)
O1−C1−N1 127.0 (2) O1−C1−N2 127.3 (2)
O2−C2−N1 125.8 (2) O2−C2−C3 127.2 (2)
N3−N2−C1 119.8 (2) N3−N2−C3 127.6 (2)
C4−N3−N2 115.8 (2) O4−N4−O5 124.9 (2)
O6−C9−N5 126.2 (3)
Table 3. Hydrogen-bond geometry. The C–H···O/X inter-
actions where the H···X distance is less than sum of van der
Waals radii and C–H···X angle is greater than 130° are con-
sidered to be significant
Symmetry codes: (i) x – 1, y, z; (ii) x – 1, y + 1, z – 1; (iii) –x + 1,
–y + 1, –z + 1; (iv) x + 1, y, z
D−H···A D−H, Å H···A, Å D···A, Å D−H···A, deg
N1−H···O6 0.83(3) 1.95(3) 2.759(3) 164(3)
C9−H···O2 1.07(4) 2.38(4) 3.251(4) 138(3)
C11−H···O2i 0.96 2.35 3.306(4) 168
C11−H···O5ii 0.96 2.57 3.339(4) 137
C3−H···O2iii 0.94(3) 2.41(3) 3.324(3) 165(2)
C4−H···O1iv 0.94(2) 2.27(2) 3.116(3) 149(2)
CRYSTALLOGRAPHY REPORTS  Vol. 61  No. 4  2016
CRYSTAL STRUCTURE AND PACKING ANALYSIS 613
found in nitrofurantoin co-crystals retrieved from the
Cambridge Crystallographic Database [20 hits, refs.
16–20].
The nitrofurantoin and dimethylformamide mole-
cules are connected by the N1–H···O6 hydrogen bond
shown in Fig. 1 to give an isolated supramolecular
adduct; the coupling of the two moieties is made more
robust by a C9–H···O2 short contact. Owing to the
scarcity of hydrogen bond donors with respect to
acceptors, the packing is completed by a number of
C–H···O interactions, listed in Table 3, which can be
considered weak hydrogen bonds. In Fig. 2, all the
interactions around a nitrofurantoin molecule are
shown. The closest contacts involve the imidazolidine
fragment of the drug molecule; the terminal nitro
group, which is known to be a poor hydrogen bonder,
is implicated only in the weakest interaction (C11–
H···O5 in Table 3).
It is worth to compare this packing mode with that
found in similar structures, where nitrofurantoine
molecule is co-crystallized with dimethylsulfoxide
(CSD code: AKEMAF) or dimethylacetamide (CSD
code: AKEMIN) [16], i.e. molecules that are very
similar to dimethylformamide as far as the size and the
functional groups are concerned. The comparison
revealed that the just described interaction pattern is
almost perfectly conserved and the packing is deter-
mined for the most part by very weak interactions. To
better visualize and analyze the intermolecular inter-
actions of the nitrofurantoin moiety in these crystals,
the Hirshfeld surface’s 2D fingergerprint plot [5, 12,
13] of the drug molecule in each of them have been
generated. The function mapped onto the Hirshfeld
surface is dnorm, i.e. the so-called normalized contact
distance; it is defined in terms of de (distance to the
nearest atoms outside), di (distance to the nearest
atoms inside) and the van der Waals radii of the two
atoms external and internal to the surface. In Fig. 3,
the Hirshfeld surface for nitrofurantoin in the title
crystal is shown. When the values of di and de for any
surface point are plotted against each other, the fin-
Fig. 1. ORTEP(III) view and atom numbering scheme for the title compound. Thermal ellipsoids are drawn at the 50% proba-
bility level. Hydrogen bond is drawn as dashed line.
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Fig. 2. N–H···O (dashed lines) and C–H···O (dotted
lines) interactions in the title compound.
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gerprint plots are obtained. Here the different colours
are related to the density of points giving that particu-
lar di–de combination: for high density the colour is
black, for moderate density the colour is white, and for
relatively few points the colour is grey. It is also possi-
ble to highlight on the plot a single contact of the type
atomtype1···atomtype2, to focus the attention on the
individual interaction types present [21]. The plots for
the title compound, AKEMIN and AKEMAF are
shown in Fig. 4. They all are very similar. Globally,
H···O interactions are the most abundant in the crystal
packing, since the percentage surface coverage for this
individual interaction type is 54.0, 46.8 and 47.6% for
the title compound, AKEMIN and AKEMAF,
respectively. This is in line with the values reported in
Table 3, which actually indicate that H···O contacts
are the most important in the packing pattern of the
present structure; accordingly, this type of interaction
Fig. 3. Nitrofurantoin Hirshfeld surface in dimethylforma-
mide co-crystal (color code: black spots = distances
shorter than the sum of vdW radii; white = distances equal
to the sum of vdW radii; grey = contacts longer than the
sum of vdW radii).
Fig. 4. Fingerprint plots for the title compound (a), AKEMAF (b) and AKEMIN (c), respectively.
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appears to have enriched occurrences in all the three
considered co-crystals. The two sharp peaks in each
plot correspond to the most important N–H···O and
C–H···O hydrogen bonding interactions. C–H···H–C
contacts produce a sharper spike in the centre of the
fingerprint plot; since the shape of the fingerprint is
related to the angle of contact [22], this means that
there are AKEMIN and AKEMAF H···H contacts
which are more direct head-to-head than in dimethyl-
formamide co-crystal.
CONCLUSIONS
A new solvated crystal containing the active phar-
maceutical ingredient nitrofurantoin has been synthe-
sized and structurally characterized with X-ray dif-
fraction. The two co-crystallized molecules are linked
via N–H···O hydrogen bonds forming bimolecular
adducts, which in turn interact with each others
through C–H···O weaker interactions. Hirshfeld anal-
ysis applied to the present structure and to other simi-
lar solvated nitrofurantoin co-crystal retrieved from
CSD have shown that this packing mode is highly
reproducible.
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